The Small Molecule Screening Facility fosters collaborative work that leads to the identification of new smallmolecule agents that inhibit cancer phenotypes in cellular or animal models and that can be furtherdeveloped for clinical evaluation in human cancer patients. The facility uses high throughput screeningtechnologies and libraries of small molecule, drug-like chemicals to identify new chemical modulators ofbiological assays provided by UW investigators, and establishes and performs biological assays oncompounds provided by UW chemists to help identify a compound's biological activity, potency or mode ofaction. .The biological endpoints address basic questions about viral entry, bacteriology, protein-DNA binding,protein-protein binding, anti-bacterial drug development, and anti-cancer drug development. The screensemploy both cell-based assays of gene expression and specific biochemical targets including protein-proteininteractions, enzyme activity and disturbance of protein-DNA binding. The assays have utilized severaldifferent modes of detection including changes in luminescence or fluorescence, changes in homogeneoustime-resolved fluorescence, and fluorescence polarization.Facility staff work with UW scientists at the earliest stages of assay development to optimize the cell numberper well, detection conditions in the multi-well plate reader and establish the statistical variation in the assayconditions with respect to well-to-well and plate-to-plate variation.f 'The facility encourages greater involvement in cancer research by UW chemists, biologists and engineersthrough their interests in small molecule chemistry and new screening methodologies.
Showing the most recent 10 out of 1528 publications
